The variation of cholesterol metabolism markers in antilipemic therapy treating coronary atherosclerotic heart disease and diabetes
Zhang Tao
Li Daorong
Dai Wenlong
Yang Hongxia
Zheng Hong
Wang Luya
Mi Shuhua
Abstract：Objective To analyze the variation of cholesterol matabolism markers in antilipemic therapy treating coronary atherosclerotic heart disease (CHD) complicated with diabetes.Methods Totally 76 patients with CHD complicated with diabetes who had not taken antilipemic drugs in 4 weeks before admission from May 2013 to May 2015 in Beijing Anzhen Hospital,Capital Medical University were enrolled.All patients were divided into 3 groups according to the level of glycosylated hemoglobin (HbA1c):group A (HbA1c 5.2％-＜ 7.0％,51 cases),group B (HbA1c 7.0％-＜ 9.0％,33 cases),group C (HbA1 c 9.0％-11.3％,20 cases).All patients were treated with rosuvastatin 10 mg/d for 4 weeks,and they were divided into 2 groups according to the level of low-density lipoprotein cholesterol (LDL-C):group D (LDL-C ＜ 2.07 mmol/L,42 cases) and group E (LDL-C≥2.07 mmol/L,34 cases).Group D was treated with rosuvastatin 10 mg/d for 8 weeks;group E was treated with rosuvastatin 10 mg/d combined with ezetimibe 10 mg/d for 8 weeks.Levels of blood lipid indexes and cholesterol matabolism markers were analyzed.Results Before treatment,total cholesterol (TC),LDL-C and campesterol(a marker of cholesterol absorption) in group C were significantly higher than those in group A [(4.7±1.4)mmol/L vs (4.4 ±0.9)mmoL/L,(2.9 ±0.7)mmol/L vs (2.8 ±0.7)mmol/L,(7.7 ± 1.9) mmol/L vs (7.1 ± 1.0) mmol/L] (all P ＜ 0.05);sitosterol (a marker of cholesterol absorption) levels in group B,C were significantly higher than that in group A [(13.6 ± 1.9) mmol/L,(12.6 ± 1.3) mmol/L vs (11.3 ± 1.5) mmol/L] (all P ＜ 0.05).After 4 weeks of treatment,there were 42 cases(55.3％) in group D and 34 cases(44.7％) in group E;TC,LDL-C and lathosterol(a marker of cholesterol synthesis) were significantly lower than those before treatment in group D and group E,sitosterol levels were significantly higher than those before treatment in both groups [group D:(3.8 ± 1.0) mmol/L vs (4.6 ± 1.1) mmol/L,(2.3 ± 0.5) mmol/L vs (3.0 ±0.9)mmol/L,(6.4 ± 1.0)mg/L vs (7.0±0.9)mg/L,(14.1 ±2.1)mg/L vs (12.5 ±2.0)mg/L;group E:(3.4 ± 1.0) mmol/L vs (4.5 ± 0.8) mmol/L,(1.9 ± 0.6) mmol/L vs (2.8 ± 0.6) mmol/L,(6.2 ± 0.7)mg/Lvs (7.4±0.9)mg/L,(13.8±2.1)mg/Lvs (11.0±0.9)mg/L](allP＜0.05).After 12 weeks of treatment,TC,LDL-C and cholesterol matabolism markers did not significantly decreased compared to those after 4 weeks of treatment in group D (P ＞ 0.05);in group E [25 cases (73.5％)],TC,LDL-C,campesterol and sitosterol were significantly lower than those after 4 weeks of treatment [(3.4 ± 0.6) mmol/L vs (3.8 ± 1.0) mmol/L,(2.0±0.7) mmol/Lvs (2.3±0.5)mmol/L,(5.5±1.7) mmol/Lvs (7.4±1.8)mmol/L,(9.3 ± 1.8) mmol/L vs (14.1 2.1) mmol/L] (all P ＜ 0.05).Conclusion Rosuvastatin combined with ezetimibe can significantly lower levels of TC,LDL-C,campesterol and sitosterol in patients with CHD and diabetes.
Keywords：Coronary atherosclerotic heart diseaseCholesterol metabolism markersRosuvastatinEzetimibe
Publication Date：2016-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：5( 1429-1433 )